Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab

LN Albers, Y Liu, NA Bo, RA Swerlick… - Journal of the American …, 2017 - Elsevier
Background Rituximab is an effective therapy for pemphigus, although relapses are
common. Objective To identify biomarkers to predict relapse of pemphigus following …
被引用次数：56 相关文章

Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab

LN Albers, Y Liu, N Bo, RA Swerlick… - Journal of the American …, 2017 - jaad.org
Background Rituximab is an effective therapy for pemphigus, although relapses are
common. Objective To identify biomarkers to predict relapse of pemphigus following …

Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab

LN Albers, Y Liu, N Bo… - Journal of the …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Rituximab is an effective therapy for pemphigus, although relapses are
common. Objective To identify biomarkers to predict relapse of pemphigus following …
[PDF] academia.edu

[PDF][PDF] Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab

LN Albers, Y Liu, N Bo - 2017 - academia.edu
Background: Rituximab is an effective therapy for pemphigus, although relapses are
common. Objective: To identify biomarkers to predict relapse of pemphigus following …

Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab.

LN Albers, Y Liu, N Bo, RA Swerlick… - Journal of the American …, 2017 - europepmc.org
Methods In this retrospective cohort study, 62 patients with pemphigus treated with 99
rituximab cycles provided longitudinal clinical scoring and biomarker data, including levels …